Multisystem Inflammatory Syndrome in Infants <12 months of Age, United States, May 2020-January 2021.

Autor:	Godfred-Cato S; From the CDC COVID-19 Response Team, Atlanta, Georgia., Tsang CA; From the CDC COVID-19 Response Team, Atlanta, Georgia., Giovanni J; From the CDC COVID-19 Response Team, Atlanta, Georgia., Abrams J; From the CDC COVID-19 Response Team, Atlanta, Georgia., Oster ME; From the CDC COVID-19 Response Team, Atlanta, Georgia., Lee EH; New York City Department of Health and Mental Hygiene, Long Island City, New York., Lash MK; New York City Department of Health and Mental Hygiene, Long Island City, New York., Le Marchand C; California Department of Health, Richmond., Liu CY; California Department of Health, Richmond., Newhouse CN; Los Angeles County Department of Public Health, Los Angeles, California., Richardson G; Louisiana Department of Health, New Orleans, Los Angeles., Murray MT; Pennsylvania Department of Health, Harrisburg, Pennsylvania., Lim S; Minnesota Department of Health, St. Paul, Minnesota., Haupt TE; Wisconsin Department of Health Services, Madison, Wisconsin., Hartley A; Tennessee Department of Health, Nashville, Tennessee., Sosa LE; Connecticut Department of Public Health, Hartford, Connecticut., Ngamsnga K; Maryland Department of Health, Baltimore, Maryland., Garcia A; Nevada Department of Health and Human Services, Reno, Nevada., Datta D; From the CDC COVID-19 Response Team, Atlanta, Georgia., Belay ED; From the CDC COVID-19 Response Team, Atlanta, Georgia.
Jazyk:	angličtina
Zdroj:	The Pediatric infectious disease journal [Pediatr Infect Dis J] 2021 Jul 01; Vol. 40 (7), pp. 601-605.
DOI:	10.1097/INF.0000000000003149
Abstrakt:	Background: Multisystem inflammatory syndrome in children (MIS-C), temporally associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been identified in infants <12 months old. Clinical characteristics and follow-up data of MIS-C in infants have not been well described. We sought to describe the clinical course, laboratory findings, therapeutics and outcomes among infants diagnosed with MIS-C. Methods: Infants of age <12 months with MIS-C were identified by reports to the CDC's MIS-C national surveillance system. Data were obtained on clinical signs and symptoms, complications, treatment, laboratory and imaging findings, and diagnostic SARS-CoV-2 testing. Jurisdictions that reported 2 or more infants were approached to participate in evaluation of outcomes of MIS-C. Results: Eighty-five infants with MIS-C were identified and 83 (97.6%) tested positive for SARS-CoV-2 infection; median age was 7.7 months. Rash (62.4%), diarrhea (55.3%) and vomiting (55.3%) were the most common signs and symptoms reported. Other clinical findings included hypotension (21.2%), pneumonia (21.2%) and coronary artery dilatation or aneurysm (13.9%). Laboratory abnormalities included elevated C-reactive protein, ferritin, d-dimer and fibrinogen. Twenty-three infants had follow-up data; 3 of the 14 patients who received a follow-up echocardiogram had cardiac abnormalities during or after hospitalization. Nine infants had elevated inflammatory markers up to 98 days postdischarge. One infant (1.2%) died after experiencing multisystem organ failure secondary to MIS-C. Conclusions: Infants appear to have a milder course of MIS-C than older children with resolution of their illness after hospital discharge. The full clinical picture of MIS-C across the pediatric age spectrum is evolving. Competing Interests: The authors have no conflicts of interest to disclose. (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu